Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study

References

• BusheCJTaylorMHaukkaJMortality in schizophrenia: a measurable clinical endpointJ Psychopharmacol2010244 suppl172520923917
   PubMed Web of Science ®Google Scholar
• TandonRKeshavanMSBasrallahHASchizophrenia, “Just the Facts”: what we know in 2008 part 1: overviewSchizophr Res20081001–341918291627
   PubMed Web of Science ®Google Scholar
• FagioliniAGoracciAThe effects of undertreated chronic medical illnesses in patients with severe mental disordersJ Clin Psychiatry200970suppl 3222919570498
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBAmerican Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia2nd edArlingtonAmerican Psychiatric Publishing Inc2010
   Google Scholar
• MarcoCAVaughanJEmergency management of agitation in schizophreniaAm J Emerg Med200523676777616182986
   PubMed Web of Science ®Google Scholar
• HasanAFalkaiPWobrockTWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistanceWorld J Biol Psychiatry201213531837822834451
   PubMed Web of Science ®Google Scholar
• MohrPPecenákJSvestkaJSwinglerDTreuerTTreatment of acute agitation in psychotic disordersNeuro Endocinol Lett2005264327335
   Web of Science ®Google Scholar
• DahlSGPharmacokinetics of antipsychotic drugs in manActa Psychiatr Scand Suppl199035837401978485
   PubMedGoogle Scholar
• Toyoaki HirataTSugiyamaNThe Japanese Association for Emergency Psychiatry. Guideline, 2015ChibaThe Japanese Association for Emergency Psychiatry2015 Available from: http://www.jaep.jp/gl/2015_all.pdfAccessed June 12, 2017
   Google Scholar
• American Psychiatric AssociationPractice guidelines for the treatment of patients with schizophrenia2nd edArlington, VAAmerican Psychiatric Association2004
   Google Scholar
• AllenMHCurrierGWCarpenterDRossRWDochertyJPExpert Consensus Panel for Behavioral Emergencies 2005. The expert consensus guideline series. Treatment of behavioral emergencies 2005J Psychiatr Pract200511suppl 15108
   PubMedGoogle Scholar
• KishiTMatsunagaSIwataNIntramuscular olanzapine for agitated patients: a systematic review and meta-analysis of randomized controlled trialsJ Psychiatr Res20156819820926228420
   PubMed Web of Science ®Google Scholar
• SuzukiHGenKA naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophreniaNeuropsychiatr Dis Treat201391281128724039430
   PubMed Web of Science ®Google Scholar
• RogersASAdverse drug events: identification and attributionDrug Intell Clin Pharm198721119159203678067
   PubMedGoogle Scholar
• Zyprexa [prescribing information] [webpage on the Internet]KobeEli Lilly Japan K.K2017 Available from: http://www.info.pmda.go.jp/go/pack/1179408E1020_1_06/Accessed June 12, 2017
   Google Scholar
• KaySROplerLAFiszbeinARamirezPMOplerMWhiteLPositive and Negative Syndrome Scale (PANSS) Technical ManualNorth TonawandaMulti-Health System Inc2006
   Google Scholar
• KatagiriHFujikoshiSSuzukiTA randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitationBMC Psychiatry2013132023311957
   PubMed Web of Science ®Google Scholar
• HuangCLHwangTChenYIntramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: an open-label, randomized controlled trialJ Formos Med Assoc2015114543844525791540
   PubMed Web of Science ®Google Scholar
• SanLArranzBQuerejetaIBarrioSDe La GándaraJPérezVA naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patientsEur Psychiatry200621853954316697151
   PubMed Web of Science ®Google Scholar
• WaltherSMoggiFHornHRapid tranquilization of severely agitated patients with schizophrenia spectrum disorders a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapineJ Clin Psychopharmacol201434112412824346752
   PubMed Web of Science ®Google Scholar
• WilsonMPPepperDCurrierGWHollomanGHJrFeifelDThe psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology WorkgroupWest J Emerg Med2012131263422461918
   PubMedGoogle Scholar
• BreierAMeehanKBirkettMA double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophreniaArch Gen Psychiatry200259544144811982448
   PubMed Web of Science ®Google Scholar
• KinonBJAhlJRotelliMDMcMullenEEfficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophreniaAm J Emerg Med200422318118615138953
   PubMed Web of Science ®Google Scholar
• ColeJBMooreJCDolanBJA prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency departmentAnn Emerg Med2017693327.e2336.e227823873
   PubMed Web of Science ®Google Scholar
• CarlsonCHornbuckleKDeLisleFKryzhanovskayaLBreierACavazzoniPDiabetes mellitus and antipsychotic treatment in the United KingdomEur Neuropsychopharmacol200616536637516356695
   PubMed Web of Science ®Google Scholar
• KessingLVThomsenAFMogensenUBAndersenPKTreatment with antipsychotics and the risk of diabetes in clinical practiceBr J Psychiatry2010197426627120884948
   PubMed Web of Science ®Google Scholar
• LambertBLCunninghamFEMillerDRDalackGWHurKDiabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophreniaAm J Epidemiol2006164767268116943266
   PubMed Web of Science ®Google Scholar
• KittipeerachonMChaichanWIntramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-blind randomized trialSchizophr Res20161762–323123827461399
   PubMed Web of Science ®Google Scholar
• MarderSRSorsaburuSDunayevichECase reports of post-marketing adverse event experiences with olanzapine intramuscular treatment in patients with agitationJ Clin Psychiatry201071443344120156413
   PubMed Web of Science ®Google Scholar
• SuzukiHGenKTakahashiYA naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in agitated elderly patients with schizophreniaTher Adv Psychopharmacol20133631432124294484
   PubMedGoogle Scholar
• ICHIntroductory guide MedDRA version 19.1McLean, VAMedDRA2016 Available from: https://www.meddra.org/sites/default/files/guidance/file/intguide_19_1_english.pdfAccessed November 27, 2017
   Google Scholar